A Study on Safety and Efficacy of Newer Anti-diabetic Drugs (Sitagliptin, Vildagliptin) in Type 2 Diabetes mellitus

Sai Theja G., K. Vinitha, V. Sushanthi Raj, S. Nafeesa Begum, E. Sam Jeeva Kumar

Abstract


Abstract

Type 2 diabetes mellitus accounts for as much as 90% of all cases of diabetes mellitus. India leads the world with largest number of diabetes subjects earning the dubious distinction of being term the “Diabetes Capital of the world”. The present study was aimed to evaluate safe and effective management of type 2 diabetes mellitus patients by using newer anti-diabetic drugs. A total of 81 patients were interviewed; out of those, 41 patients were recruited as per inclusion and exclusion criteria. Then newer anti-diabetic drugs were administered to the patients. Then the patients were monitored closely for any changes and periodic estimation of blood glucose levels, and all the parameters had been taken on interval of once in a 30 days and followed up to 6 months. Both the drugs led to a significantly higher proportion of patients achieving the glycemic goal of HbA1c and lt; 7%, as well as baseline average values of FBS, RBS and PPBS are 167.43, 195.53, and 196.60 respectively; after 24 weeks of therapy, the above parameters showed significant reduction in glycemic levels as 135.21, 155.68 and 157.0 respectively. The short term usage of these drugs is safer but we cannot confirm that these are safe, and in attendance, it necessitates the prolong studies to be conventional and precise for safety and efficacy.

 

Keywords: Fasting blood sugar, glycated hemoglobin, post prandial blood sugar, random blood sugar, Type 2 diabetes mellitus.


Full Text:

PDF

References


Alvin C. Power; Diabetes mellitus. Harrisons; Principal of Internal Medicine; 17th edition; volume 2; 2275-2304. NCES.

Colagiuri S, Borch-Johnsen K, Glümer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48 (8): 1459-1463.

Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H.et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28 (9): 21302135.

V Mohan, S Sandeep, Epidemiology of type-2diabetes; Indian scenario. Indian J Med Res 2007 March; 217-230.

Shah SK, Saikia M, Burman NN, Snehalatha A. Risk factors of type 2 diabetes in urban population in north eastern India. Int J Diabetes Dev Countries 1999; 19: 144-147.

Enrique Z. Fisman, Alexander Tenenbaum Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Fisman and Tenenbaum Cardiovasc Diabetol (2015).

P. Aschner1, H. L. Katzeff2, H. Guo 2, S. Sunga2, D. Williams-Herman2, K. D. Kaufman2 et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type2 diabetes obesity and metabolism • march 2010. Volume 12 No. 3: 250-61.

Abilash Sathyanarayanan1*, Elvin Benny2, Jenit Osborn3, Senthil Kumar4, Suresh Prabhu4, Anil C. Mathew 3 . Factors Associated with Poor Sleep Quality among Type 2 Diabetes Mellitus Patients on Insulin Therapy Journal of Diabetes Mellitus, 2015, 5: 206-210.

Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008; 4: 743–751.

BO Ahren, MD, PHD1 Giovanni pacini, PHD2 James E. Foley, PHD3 Anja schweizer, PHD4 Improved Meal-Related Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin Treated Patients With Type 2 Diabetes Over 1Year diabetes care, volume 28, number 8, august 2005, pg no. 1936–40.

Stein SA1, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs Expert Opin Drug Saf. 2013 March; 12(2): pg no.153-175.

Paul Craddy, Hannah-Jayne Palin, K. Ian Johnson Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Ther (2014).

Pablo Aschner, MD1 mark S. Kipnes, MD2 Jared K. Lunceford, PHD3 Matilde sanchez, PHD3 Carolyn Mickel, MS3 Debora E. et al Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients with Type 2Diabetes. Diabetes care, volume 29, number 12, December 2006, page 263237.

I. Raz & M. Hanefeld & L. Xu & C. Caria & D. Williams-Herman & H. Khatami Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) page no.2564–71.

YujiTajiri,1 SeikoKawano,2 SaoriHirao,2 TamamiOshige,1 ShinpeiIwata,1 YasuhiroOno,3 et al Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a HemoglobinA1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes. Received 10 March 2014; Accepted 5 June 2014; Published 3 August 2014.

Joseph T. Dipiro, Robert L. Tablet. Dipiro, Pharmacotherapy a Pathological Approach; Seventh edition; 1205-42.

Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008; 4: 743–751.

Sajith et al., Medication adherence to antidiabetic therapy in patients with type 2 diabetes mellitus. International Journal of Pharmacy and Pharmaceutical Sciences. 2014, 6(2): 564-570.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Research & Reviews: A Journal of Pharmacology